毛利人患肺癌的死亡率是非毛利人的三倍。特曼瓦塔基地区的人口为900,000人，其中30%是毛利人。我们对发展和诊断肺癌以及这些特征的种族差异知之甚少。本研究旨在探讨毛利人和非毛利人新诊断肺癌患者的发病率和特征的差异。我们从地区登记处确定了患者，根据2013年和2018年人口普查数据计算了发病率。对比了毛利人和非毛利人的患者和肿瘤特征。分析采用了Χ2检验和逻辑回归模型对分类变量，学生t检验对连续变量。共纳入了4933名患者，其中1575名为毛利人，3358名为非毛利人。毛利人的年龄标准化发病率(每10万人236例)是非毛利人的3.3倍。毛利人患病晚期的可能性为非毛利人的1.3倍，患小细胞肺癌的可能性为非毛利人的1.97倍。毛利人更有可能患有共病，慢性阻塞性肺病、心血管疾病和糖尿病。他们还存在更高水平的社会剥夺，更年轻、女性和吸烟者居多。研究结果指出需要解决早期诊断的障碍，并有必要改变系统，包括引入以毛利人为重点的肺癌筛查项目。还需要预防方案来解决影响肺癌结果的共病，同时继续强调打造一个无烟新西兰。© 2023 Royal Australasian College of Physicians.

Māori have three times the mortality from lung cancer compared with non-Māori. The Te Manawa Taki region has a population of 900 000, of whom 30% are Māori. We have little understanding of the factors associated with developing and diagnosing lung cancer and ethnic differences in these characteristics.To explore the differences in the incidence and characteristics of patients with newly diagnosed lung cancer between Māori and non-Māori.Patients were identified from the regional register. Incidence rates were calculated based on population data from the 2013 and 2018 censuses. The patient and tumour characteristics of Māori and non-Māori were compared. The analysis used Χ2 tests and logistic models for categorical variables and Student t tests for continuous variables.A total of 4933 patients were included, with 1575 Māori and 3358 non-Māori. The age-standardised incidence of Māori (236 per 100 000) was 3.3 times higher than that of non-Māori. Māori were 1.3 times more likely to have an advanced stage of disease and 1.97 times more likely to have small cell lung cancer. Māori were more likely to have comorbidities, chronic obstructive pulmonary disease, cardiovascular disease and diabetes. They also had higher levels of social deprivation and tended to be younger, female and current smokers.The findings point to the need to address barriers to early diagnosis and the need for system change including the need to introduce a lung cancer screening focussing on Māori. There is also the need for preventive programmes to address comorbidities that impact lung cancer outcomes as well as a continued emphasis on creating a smoke-free New Zealand.© 2023 Royal Australasian College of Physicians.